Ketamine Therapy for Depression

Considering Ketamine for Depression

When depression keeps returning or treatment has not brought enough relief, another option can feel hopeful and hard to evaluate. Ketamine-based treatment can help some people with treatment-resistant depression. The medicine, the setting, and the follow-up plan matter as much as the name on the clinic’s website.^[1][2]

Ketamine therapy for depression usually means off-label ketamine treatment or treatment with esketamine, sold as Spravato. These are related medicines with different approval and monitoring requirements. Considering either does not mean you have ketamine addiction; a careful assessment should address depression and any substance-use concerns without assuming a diagnosis.^[3][4]

If you are thinking about suicide or struggling with emotional distress, call or text 988 in the United States. Support is available around the clock. Do not wait for a ketamine appointment to seek crisis support.^[5]

Ketamine, Spravato, and Compounded Products

Ask for the exact medicine and route before comparing treatment programs. Esketamine is a component of racemic ketamine, rather than a brand name for the same formulation. The distinction matters because approval and clinical evidence apply to particular products and uses.^[3][2]

How the Options Differ

Spravato is a specific prescription nasal spray. A compounded ketamine nasal spray is not Spravato, even though both are administered through the nose. The same distinction applies to tablets or troches, which are lozenges prepared by a compounding pharmacy.^[3][4]

Off-label does not mean there is no research. It does mean the FDA has not approved that medicine for the proposed use. Similarly, a product can qualify for compounding exemptions without becoming FDA-approved. These are separate questions to discuss with the prescriber.^[3]

What Treatment Resistance Means

Treatment-resistant depression refers to depression that has not improved adequately with appropriate previous treatment. A specialist needs to review what was tried, for how long, at what dose, and with what response or side effects. The label is a description of the treatment history, not a judgment about your effort.^[1][2]

Spravato’s treatment-resistant depression indication allows use alone or with an oral antidepressant. Its separate indication for depressive symptoms in adults with major depression and acute suicidal thoughts or behavior requires an oral antidepressant. Neither indication establishes that Spravato prevents suicide or removes the need for hospitalization when necessary.^[4]

How Well Does Ketamine Therapy Work?

Ketamine and esketamine can reduce depressive symptoms, sometimes rapidly, but not everyone improves. A 2022 review of 36 randomized trials found better response and remission outcomes with ketamine-based treatment than with placebo. Most trials involved treatment-resistant depression, and the longest acute treatment period was eight weeks.^[1]

In that review, response meant a defined improvement in symptoms; remission meant symptoms fell below a defined threshold. The estimated benefit became smaller when the authors adjusted for publication bias, the possibility that favorable studies were more likely to be published. Benefit remained, but one striking result should not become a promise.^[1]

The Product and Population Matter

The trials used different formulations, routes, schedules, and comparison treatments. Most studied major depressive disorder; only three focused exclusively on bipolar depression. Those differences matter when a service uses a general claim about ketamine to promote a particular treatment package.^[1]

Ask, “Was this result measured in people with my diagnosis, using this medicine in this setting?” Evidence for supervised IV ketamine or Spravato cannot automatically establish the benefit or safety of a different compounded preparation used at home.^[3][1][2]

How Long Benefits Last

Early improvement can fade. A 2022 maintenance review found promising results across several routes, but the evidence included only three randomized trials alongside smaller or uncontrolled studies. The authors called for stronger long-term research. Continued benefit and the best maintenance plan remain individual treatment decisions.^[6]

For Spravato treatment-resistant depression care, the label directs the clinician to assess benefit after the first four weeks before deciding whether treatment should continue. A plan should explain how response will be tracked, how visits may change, and what will happen if benefits are absent or short-lived.^[4][2]

Ketamine Compared With ECT

Electroconvulsive therapy, or ECT, is another treatment considered for severe depression. A 2023 trial randomized 403 people with treatment-resistant major depression without psychosis⁠.^[7]

During the initial three-week treatment phase, symptoms improved enough to count as a response in 55.4% of ketamine recipients and 41.2% of ECT recipients.^[7] Response meant symptoms improved by at least half on a depression questionnaire.^[7]

The trial met its planned test of whether ketamine was not substantially less effective than ECT. Participants knew their treatment, and some withdrew before treatment began. An earlier review of six trials in hospitalized patients favored ECT for reducing depression severity. These findings support discussing the options in context, not choosing from a single percentage.^[8][7]

Who Should Be Assessed Before Treatment?

A treatment decision starts with your diagnosis, treatment history, and health risks. Share your current prescriptions, over-the-counter medicines, alcohol or other substance use, and any past difficulties controlling use. This information helps the clinician weigh benefit and risk rather than automatically excluding you because of your history.^[4][2]

Medical and Mental Health History

Spravato can raise blood pressure. Its label lists certain blood-vessel disorders, previous bleeding within the brain, and allergy to ketamine or esketamine among reasons it should not be used. Other heart or blood-vessel conditions require an individual benefit-risk assessment.^[4]

A history of psychosis also needs discussion. Ketamine can affect perception and thinking, and an assessment must distinguish the symptoms of depression from other conditions that could change the treatment choice. Bring questions about past unusual perceptions, episodes of unusually elevated mood, or previous psychiatric treatment.^[4][2]

Pregnancy and Breastfeeding

Spravato is not recommended during pregnancy because of concern about fetal harm, and breastfeeding is not recommended during treatment. Human pregnancy data are limited. Untreated depression can also carry risks, so pregnancy or pregnancy planning needs a prompt discussion with the treating clinician rather than a medication decision made alone.^[4]

Other Medicines and Substances

Alcohol, opioids, benzodiazepines, and other medicines that reduce alertness can increase sedation with Spravato. Some stimulants and other medicines can increase blood-pressure concerns. Ask the prescriber which medicines need review before a session; do not change them yourself.⁠^[4]

Someone taking medication for an opioid use disorder should make sure the depression prescriber and addiction clinician have an accurate medication list. That coordination helps the team evaluate interactions and protect the existing treatment plan while discussing a new one.^[4][2]

What Happens During a Treatment Visit?

Supervision provides monitoring and a response to side effects; it does not make treatment risk-free. Spravato must be taken under healthcare supervision in a certified setting. Its restricted safety program, called a REMS, requires at least two hours of monitoring after administration and an assessment before discharge.^[4]

Before the Session

The treatment team checks blood pressure and reviews relevant symptoms and medicines. For Spravato, the label advises avoiding food for at least two hours and liquids for at least 30 minutes before administration because nausea and vomiting can occur. Follow the instructions for the exact product you are prescribed.^[4]

Arrange transportation home before the visit. Spravato users should not drive or operate machinery until the next day after a restful sleep. For IV ketamine, 2021 expert guidance likewise recommends reliable transport and waiting until after a night’s sleep before driving.^[4][2]

During Monitoring

Spravato can cause sleepiness, dizziness, nausea, increased blood pressure, and dissociation. Breathing can also become dangerously slowed. Monitoring includes breathing and blood pressure, not only whether the experience feels comfortable.^[4]

Tell the treatment team if symptoms are distressing or changing. Severe headache, chest pain, shortness of breath, vision changes, or a seizure can require immediate medical attention. If a medical emergency occurs after leaving, seek emergency care rather than waiting for the next appointment.^[4]

IV ketamine for depression does not have the same product-specific REMS as Spravato. Expert guidance recommends checking breathing, blood-pressure stability, alertness, and psychiatric effects before discharge. The minimum adequate observation period for IV ketamine was not established in that guidance; a clinic should explain its own monitoring and discharge plan.^[2]

Between Visits

Follow-up should address whether depression is improving and whether side effects or use concerns are developing. Ask who to contact if mood worsens, symptoms return, or you cannot attend the next appointment. Changes in schedule should be reviewed with the treating team.^[4][2]

Useful questions for follow-up include:

• What has changed in my symptoms and daily life since treatment began?
• Does the benefit last between appointments?
• Have I had urinary symptoms, memory concerns, or troublesome dissociation?
• Am I feeling pressure to use more than prescribed or outside the treatment plan?
• What is the next step if the benefit no longer outweighs the burden or risks?^[4][2]

Addiction Risk and At-Home Treatment

Ketamine has misuse potential, and medical treatment needs a plan for recognizing it. Spravato’s label calls for assessment before prescribing and monitoring during treatment. A history of substance use disorder calls for careful consideration, not an assumption that every person with that history will misuse ketamine.^[4]

Talk openly about craving, taking more than directed, or use outside the agreed plan. If these concerns develop, the next step is a clinical discussion that addresses both depression and substance use. Help for problematic ketamine use serves a different need from choosing a depression treatment.^[4][2]

Compounded Ketamine Needs Separate Questions

A compounded oral or nasal product may differ from the products in the strongest trials. The formulation, route, monitoring, and patient population all affect whether research findings apply. A familiar drug name or a prescription alone does not establish that the proposed care matches the evidence.^[3][1][2]

In a June 2026 warning letter to one online seller, the FDA described unapproved products and failures to meet compounding requirements. That finding concerned that seller; it was not a ruling that all compounded ketamine treatment is unlawful. It does reinforce the need to confirm the product, prescriber, pharmacy, and supervision before paying.^[3]

Spravato is not a take-home medicine. Certified pharmacies dispense it to certified healthcare settings. If a service describes a take-home spray as the same as Spravato, ask it to identify the exact product and explain that claim.^[4]

Costs and Questions for a Ketamine Provider

Ask for the full course of care and its costs, not just the price of the medicine. Even generic IV ketamine involves administration and monitoring costs that may not be insured. Appointment time, transportation, repeated visits, and follow-up can affect whether a treatment plan is workable.^[2]

Before committing to a package, ask the provider and your insurer, if applicable, to confirm:

• The exact product and whether the proposed use is approved or off-label.
• Assessment, medicine, monitoring, and follow-up charges.
• What coverage or prior authorization has been confirmed, and what remains unconfirmed.
• How many initial visits are proposed and when benefit will be reassessed.
• Who responds to side effects or a worsening mood between appointments.
• What happens to the plan and charges if treatment is stopped early.^[3][4][2]

You can start with: “I want to understand why this treatment fits my depression, how you will monitor me, and what I would pay if I need ongoing care.” Ask for the answers in writing so you can compare the actual services being offered.

Taking the Next Step

Bring your treatment history and the questions above to the clinician managing your depression. The next useful step is an assessment, not a commitment to a treatment package. The choice should account for the evidence, your health, your preferences, and the practical work of continuing care.^[2]